Aranesp/Procrit Trial Tumor Biopsy Collection Not Feasible, Cmte. Says
Executive SummaryAmgen's and Johnson & Johnson's erythropoietin survival studies cannot logistically include a tumor biopsy component, FDA's Oncologic Drugs Advisory Committee said May 4
You may also be interested in...
The court will decide whether a party seeking class certification must show that a company’s alleged misrepresentations are material; investors claim Amgen misrepresented the safety of Aranesp and Epogen prior to a May 2004 FDA advisory committee meeting.